Skip to main content

Table 3 Crude and adjusted Hazards Ratios for Carcinosarcoma progression-free survival (PFS) estimated by univariate analysis and multivariate analysis

From: The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma

Clinicopathological features Univariate analysis Multivariate analysis
HR 95%CI p-value HR 95%CI p-value
Age (<  60 vs. ≥ 60) 1.03 0.99–1.07 0.171 1.03 0.99–1.07 0.111
Stage (I/II vs III/IV) 0.37 0.16–0.84 0.017
Residual disease (R1/2 vs R0) 4.19 2.13–8.25 0.001 3.09 1.34–7.08 0.008
Adjuvant radiotherapy (Yes vs No) 0.57 0.30–1.08 0.087 0.66 0.34–1.26 0.213
LVI (present vs absent) 1.06 0.50–2.25 0.872 1.05 0.49–2.22 0.906
Histological subtype (Homologous vs Heterologous) 0.83 0.39–1.78 0.631 0.94 0.44–2.02 0.885
CD3_E (high vs low) 0.58 0.31–1.08 0.086 0.67 0.26–1.27 0.229
CD3_S (high vs low) 0.48 0.15–1.57 0.225 0.62 0.19–2.07 0.439
CD4_E (high vs low) 0.39 0.21–0.74 0.004 0.43 0.23–0.82 0.010
CD4_S (high vs low) 0.62 0.80–3.21 0.184 0.60 0.30–1.20 0.153
CD8_E (high vs low) 0.67 0.35–1.29 0.232 0.61 0.31–1.19 0.151
CD8_S (high vs low) 0.86 0.42–1.75 0.669 0.71 0.34–1.48 0.364
FOXP3_E (high vs low) 0.55 0.26–1.17 0.120 0.54 0.26–1.16 0.115
FOXP3_S (high vs low) 0.41 0.14–1.15 0.090 0.42 0.15–1.19 0.103
PD-1_E (high vs low) 0.47 0.25–0.90 0.022 0.54 0.28–1.04 0.065
PD-1_S (high vs low) 0.66 0.31–1.41 0.286 0.73 0.34–1.56 0.420
PD-L1_E (high vs low) 0.47 0.25–0.88 0.019 0.45 0.24–0.84 0.013
PD-L1_S (high vs low) 0.28 0.12–0.67 0.004 0.30 0.12–0.74 0.008
PD-L2_E (high vs low) 0.48 0.22–1.06 0.070 0.62 0.28–1.38 0.241
PD-L2_S (high vs low) 0.46 0.16–1.31 0.147 0.43 0.15–1.22 0.114
CD4/FOXP3_E ratio (high vs low) 0.57 0.31–1.04 0.067 0.63 0.34–1.16 0.141
CD4/FOXP3_S ratio (high vs low) 1.43 0.76–2.67 0.267 1.65 0.87–3.11 0.120
CD8/FOXP3_E ratio (high vs low) 0.74 0.39–1.41 0.363 0.84 0.44–1.60 0.605
CD8/FOXP3_S ratio (high vs low) 2.27 1.21–4.26 0.010 2.05 1.08–3.85 0.026
CD8/CD4_E ratio (high vs low) 0.61 0.24–1.56 0.299 0.51 0.20–1.33 0.171
CD8/CD4_S ratio (high vs low) 1.69 0.78–3.67 0.186 1.87 0.86–4.10 0.113
  1. All variables were adjusted for staging in multivariate analysis. Significant P-values are emboldened
  2. LVI Lymphovascular Invasion, E Epithelial Component, S Sarcomatous Component, ER Estrogen Receptor, PR Progesterone Receptor, CD3 Cluster of Differentiation 3, CD4 Cluster of Differentiation 4, CD8 Cluster of Differentiation 8, FOXP3 Forkhead Box P3, PD-1 Programmed Cell Death Protein 1, PD-L1 Programmed Death-Ligand 1, PD-L2 Programmed Death-Ligand 2